Inventor · disambiguated record
Samuel Moser
Also filed as: MOSER SAMUEL
8 granted patents·14 pending applications·52 citations·filing 2007–2022
85Inventor score
Top patents by PatentIndex Score
22 records- 0194US10683369B2Monoclonal antibodies against BCMAENGMAB SARL·Filed 2016·Granted Jun 16, 2020·14 cites·21 claims
- 0292US9963513B2Method for the selection of antibodies against BCMAENGMAB AG·Filed 2014·Granted May 8, 2018·19 cites·5 claims
- 0387US10253104B2Bispecific antibodies against CD3ϵ and BCMAENGMAB AG·Filed 2015·Granted Apr 9, 2019·10 cites·16 claims
- 0484US10077315B2Bispecific antibodies against CD3 and BCMAENGMAB AG·Filed 2014·Granted Sep 18, 2018·6 cites·5 claims
- 0580US10851171B2Method for the selection of antibodies against BCMAENGMAB SARL·Filed 2018·Granted Dec 1, 2020·1 cites·4 claims
- 0678US10584178B2Bispecific HER2 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Granted Mar 10, 2020·2 cites·6 claims
- 0773US2023322957A1Monoclonal antibodies against bcmaENGMAB SARL·Filed 2022·Application pending·0 cites
- 0868US2022073646A1Bispecific antibodies with tetravalency for a costimulatory tnf receptorHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 0968US2021070873A1Method for the selection of antibodies against bcmaENGMAB SARL·Filed 2020·Application pending·0 cites
- 1063US11787873B2Bispecific HER2 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2020·Granted Oct 17, 2023·0 cites·17 claims
- 1162US2020283545A1Monoclonal antibodies against bcmaENGMAB SARL·Filed 2020·Application pending·0 cites
- 1257US2019211113A1Bispecific antibodies with tetravalency for a costimulatory tnf receptorHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 1356US2020255521A1Bispecific antibodies against cd3epsilon and ror1ENGMAB SARL·Filed 2020·Application pending·0 cites
- 1454US2008226635A1Antibodies against insulin-like growth factor I receptor and uses thereofKOLL HANS·Filed 2007·Application pending·0 cites
- 1551US2017247467A1Bispecific antibodies with tetravalency for a costimulatory tnf receptorHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 1650US2016297881A1BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1ENGMAB AG·Filed 2014·Application pending·0 cites
- 1746US11952421B2Bispecific antibodies against CD3EPSILON and ROR1BRISTOL MYERS SQUIBB CO·Filed 2015·Granted Apr 9, 2024·0 cites·6 claims
- 1844US2012076778A1Antibodies Against Insulin-Like Growth Factor I Receptor and Uses ThereofKOLL HANS·Filed 2011·Application pending·0 cites
- 1939US2010247533A1TREATMENT WITH A HUMANIZED ANTI-EGFR IgG1 ANTIBODY AND IRINOTECANFRIESS THOMAS·Filed 2010·Application pending·0 cites
- 2038US2018282410A1Anti-cd3xrob04 bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 2134US2017327579A1Bispecific antibodies against cd3epsilon and bcmaENGMAB AG·Filed 2015·Application pending·0 cites
- 2233US2017306044A1Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancerENGMAB AG·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Samuel Moser files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →